Bio-Techne Corp Stock Price, News & Analysis

On February 2, 2023, Bio-Techne Corporation (NASDAQ: TECH) declared a quarterly dividend of $0.08 per share for the quarter ended December 31, 2022. This dividend will be payable on February 27, 2023 to shareholders of record on February 13, 2023. Bio-Techne, a global leader in life sciences, reported approximately $1.1 billion in net sales for fiscal 2022 and employs around 3,000 staff worldwide. The Board will evaluate future dividends quarterly. The company’s innovative tools and reagents play a critical role in research and diagnostics.

Bio-Techne Corporation (NASDAQ: TECH) announced the appointment of Shane Bohnen as Senior Vice President and General Counsel, effective March 3, 2023. Bohnen succeeds Brenda Furlow, who is retiring after nine years of significant contributions, including establishing the legal and compliance functions and leading corporate sustainability initiatives. Bohnen has over 20 years of legal experience, including his role as Associate General Counsel at Bio-Techne since 2019, where he managed M&A activities and ESG initiatives. Chuck Kummeth, CEO, emphasized Bohnen's extensive knowledge and leadership as vital for the company's growth strategy.

Bio-Techne Corporation (NASDAQ: TECH) launched its ProteinSimple-branded MauriceFlex™ system during the WCBP conference on Jan. 26, 2023, in Washington D.C. This innovative system enables protein charge variant fractionation along with routine cIEF and CE-SDS assays, streamlining protein characterization workflows. MauriceFlex™ distinguishes itself by allowing cIEF-based fractionation without the extensive method development and preparation typically required. A major biotech company showcased the system's capabilities in analyzing charge variant fractions of a therapeutic dual variable domain antibody. According to Will Geist, President of Protein Sciences, MauriceFlex™ accelerates therapeutic molecule analysis, enhancing market readiness.

Bio-Techne Corporation (NASDAQ: TECH) announced a conference call and webcast to discuss its second quarter 2023 financial results on February 2, 2023, at 8:00 a.m. CST. Investors can join the call by dialing 1-877-407-9208 or through the webcast link provided. A recorded replay will be available from 11:00 a.m. CST on February 2 until 11:00 p.m. CST on March 2. The company, noted for high-quality protein and reagent solutions, generated approximately $1.1 billion in net sales in fiscal 2022 and employs around 3,000 people globally.

Bio-Techne Corporation (NASDAQ: TECH) has introduced the RNAscope Plus smRNA-RNA detection assay, expanding its Advanced Cell Diagnostics (ACD) portfolio. This assay allows simultaneous fluorescent detection of small regulatory RNAs and target RNAs within tissue samples at single-cell resolution. Designed for scalability, it supports extensive studies on the Leica Bond Rx platform. The assay enhances the research of oligonucleotide therapies, crucial for developing targeted treatments for various diseases. Bio-Techne reported approximately $1.1 billion in net sales for fiscal 2022.

Bio-Techne Corporation (NASDAQ: TECH) announced that CEO Chuck Kummeth will present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 8:15 a.m. PST. The presentation will be accessible via a live webcast on Bio-Techne's Investor Relations website. Bio-Techne specializes in manufacturing purified proteins, reagents, and diagnostic products, generating approximately $1.1 billion in net sales in fiscal 2022. The company employs around 3,000 people globally and offers a wide range of scientific products for molecular diagnostics and biological research.

Bio-Techne Corporation (NASDAQ: TECH) announced the launch of MitoBrilliant^™ probes on Dec. 5, 2022. These innovative fluorescent probes are designed for effective imaging and tracking of mitochondria in live and fixed cells. The MitoBrilliant^™ Live probes allow dynamic monitoring of mitochondrial membrane potential, while MitoBrilliant^™ 646 offers high performance for post-fixation imaging. Developed using Janelia Fluor^™ technology, these probes enhance modern imaging capabilities crucial for scientific research. Bio-Techne reported $1.1 billion in net sales in fiscal 2022.

Bio-Techne (NASDAQ: TECH) has announced a collaboration with Oxford Nanopore Technologies to develop innovative assays for reproductive health and carrier screening. This partnership aims to combine Asuragen's PCR technology with Oxford Nanopore's DNA sequencing capabilities to create a streamlined workflow for identifying challenging genes. The new integrated system is expected to analyze 11 critical genes associated with severe genetic disorders, covering approximately 70% of pathogenic variants. The collaboration addresses the growing need for efficient carrier screening solutions.

Bio-Techne Corporation (NASDAQ: TECH) has announced that CEO Chuck Kummeth will present at the Fifth Annual Evercore ISI HealthCONx Conference on November 29, 2022, at 8:50 a.m. EST. The presentation will be available via a live webcast on Bio-Techne's Investor Relations website. The company is a prominent developer of purified proteins, reagents, and diagnostic products, generating approximately $1.1 billion in net sales in fiscal 2022. Bio-Techne serves biomedical researchers and clinical laboratories with a wide range of innovative solutions, employing around 3,000 staff globally.